Silencing CCT3 induces ferroptosis through the NOD1-NF-κB signaling pathway in bladder cancer.
Ferroptosis
/ genetics
Humans
Urinary Bladder Neoplasms
/ genetics
NF-kappa B
/ metabolism
Signal Transduction
Animals
Cell Line, Tumor
Nod1 Signaling Adaptor Protein
/ metabolism
Mice
Chaperonin Containing TCP-1
/ metabolism
Cell Proliferation
Gene Expression Regulation, Neoplastic
Gene Silencing
Apoptosis
/ genetics
Cell Movement
/ genetics
Mice, Nude
Bladder cancer
CCT3
Ferroptosis
The NOD1-NF-κB signaling pathway
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 10 2024
31 10 2024
Historique:
received:
28
06
2024
accepted:
16
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Bladder cancer (BCa) is a lethal malignancy of the urinary system and exhibits a poor prognosis. Chaperonin-containing tailless complex polypeptide 1 subunit 3 (CCT3) acts as an oncogene in various tumors, whereas its effect on BCa remains unknown. We identified the ferroptosis-associated differentially expressed genes through bioinformatic analysis and selected CCT3 for further verification. The levels of cell viability, apoptosis, migration, invasion, and proliferation were measured to clarify the effect of silencing CCT3 on BCa cells. Then we evaluated the role of CCT3 knockdown in vivo. Ferroptosis was assessed by the expression detection of the ferroptosis-related proteins. The underlying mechanism was predicted by RNA sequencing and verified by an agonist for nucleotide-binding and oligomerization domain 1 (NOD1). Western blotting was conducted to detect the protein expression of NOD1, nuclear factor kappa B (NF-κB) inhibitor alpha (IκBα), and phospho-IκBα (p-IκBα). In vitro, down-regulation of CCT3 suppressed the cell viability, migration, invasion, and proliferation, as well as induced apoptosis of BCa cells. In vivo, silencing CCT3 elevated the body weight of mice and suppressed the BCa progression. In addition, CCT3 knockdown could induce ferroptosis in vitro and in vivo. CCT3 knockdown suppressed the expression of NOD1 and p-IκBα/IκBα and the NOD1 agonist could reverse the effect of CCT3 suppression on BCa in vitro and in vivo. In summary, our findings demonstrate that silencing CCT3 inhibits BCa via induction of ferroptosis and suppression of the NOD1-NF-κB pathway.
Identifiants
pubmed: 39478031
doi: 10.1038/s41598-024-76724-z
pii: 10.1038/s41598-024-76724-z
doi:
Substances chimiques
NF-kappa B
0
Nod1 Signaling Adaptor Protein
0
Chaperonin Containing TCP-1
EC 3.6.1.-
NOD1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26188Subventions
Organisme : Project supported by the Sichuan Natural Science Foundation
ID : 2023NSFSC0331
Organisme : Project supported by the Sichuan Natural Science Foundation
ID : 2023NSFSC0331
Organisme : Project supported by the Sichuan Natural Science Foundation
ID : 2023NSFSC0331
Organisme : Project supported by the Sichuan Natural Science Foundation
ID : 2023NSFSC0331
Organisme : Project supported by the Sichuan Natural Science Foundation
ID : 2023NSFSC0331
Organisme : Project supported by the Sichuan Natural Science Foundation
ID : 2023NSFSC0331
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74 (1), 12–49 (2024).
doi: 10.3322/caac.21820
pubmed: 38230766
Lopez-Beltran, A. et al. Advances in diagnosis and treatment of bladder cancer. BMJ 384, e076743 (2024).
doi: 10.1136/bmj-2023-076743
pubmed: 38346808
Dyrskjøt, L. et al. Bladder cancer. Nat. Rev. Dis. Primers. 9 (1), 58 (2023).
doi: 10.1038/s41572-023-00468-9
pubmed: 37884563
pmcid: 11218610
Beckabir, W. et al. Spatial relationships in the tumor microenvironment demonstrate association with pathologic response to neoadjuvant chemoimmunotherapy in muscle-invasive bladder cancer. Eur. Urol. 85(3), 242–253 (2024).
doi: 10.1016/j.eururo.2023.11.008
pubmed: 38092611
Zang, Y. et al. An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and end results (SEER) study. Ann. Transl Med. 8 (23), 1587 (2020).
doi: 10.21037/atm-20-2108
pubmed: 33437786
pmcid: 7791213
Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer. 22 (7), 381–396 (2022).
doi: 10.1038/s41568-022-00459-0
pubmed: 35338310
pmcid: 10243716
Yu, Q. et al. EGCG attenuated acute myocardial infarction by inhibiting ferroptosis via miR-450b-5p/ACSL4 axis. Phytomedicine. 119, 154999 (2023).
doi: 10.1016/j.phymed.2023.154999
pubmed: 37597361
Zhang, C. et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol. Cancer. 21 (1), 47 (2022).
doi: 10.1186/s12943-022-01530-y
pubmed: 35151318
pmcid: 8840702
Xu, H. et al. Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends Mol. Med. 27 (9), 856–867 (2021).
doi: 10.1016/j.molmed.2021.06.014
pubmed: 34312075
Lee, J. & Roh, J. L. Induction of ferroptosis in head and neck cancer: a novel bridgehead for fighting cancer resilience. Cancer Lett. 546, 215854 (2022).
doi: 10.1016/j.canlet.2022.215854
pubmed: 35973621
Zeng, F. et al. Ferroptosis: a new therapeutic target for bladder cancer. Front. Pharmacol. 13, 1043283 (2022).
doi: 10.3389/fphar.2022.1043283
pubmed: 36408230
pmcid: 9669411
Jiang, P. et al. FLRT2 suppresses bladder cancer progression through inducing ferroptosis. J. Cell. Mol. Med. 28 (5), e17855 (2023).
doi: 10.1111/jcmm.17855
pubmed: 37480224
pmcid: 10902570
Sun, Y. et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell. Death Dis. 12 (11), 1028 (2021).
doi: 10.1038/s41419-021-04306-2
pubmed: 34716292
Liu, W. et al. Current understanding on the role of CCT3 in cancer research. Front. Oncol. 12, 961733 (2022).
doi: 10.3389/fonc.2022.961733
pubmed: 36185198
Temiz, E., Koyuncu, İ. & Sahin, E. CCT3 suppression prompts apoptotic machinery through oxidative stress and energy deprivation in breast and prostate cancers. Free Radic Biol. Med. 165, 88–99 (2021).
doi: 10.1016/j.freeradbiomed.2021.01.016
pubmed: 33508424
Dou, L. & Zhang, X. Upregulation of CCT3 promotes cervical cancer progression through FN1. Mol. Med. Rep. 24 (6), 12496 (2021).
Chen, S. et al. Suppression of CCT3 inhibits tumor progression by impairing ATP production and cytoplasmic translation in lung adenocarcinoma. Int. J. Mol. Sci. 23 (7), 3983 (2022).
Wang, K. et al. Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma. BMC Mol. Cell. Biol. 23 (1), 25 (2022).
doi: 10.1186/s12860-022-00424-7
pubmed: 35773623
pmcid: 9245217
Wasmuth, S. et al. Phenotypic Differences in Primary Murine Microglia Treated with NOD1, NOD2, and NOD1/2 agonists. J. Mol. Neurosci. 70 (4), 600–609 (2020).
doi: 10.1007/s12031-019-01466-x
pubmed: 31907866
Wang, X. et al. Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/β-catenin pathways. Genes Dis. 11 (2), 1050–1065 (2024).
doi: 10.1016/j.gendis.2023.03.031
pubmed: 37692489
Compérat, E. et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 400 (10364), 1712–1721 (2022).
doi: 10.1016/S0140-6736(22)01188-6
pubmed: 36174585
Guan, Q., Zhou, L. L. & Dong, Y. B. Ferroptosis in cancer therapeutics: a materials chemistry perspective. J. Mater. Chem. B. 9 (43), 8906–8936 (2021).
doi: 10.1039/D1TB01654G
pubmed: 34505861
Liu, J. et al. Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics. J. Cancer Res. Clin. Oncol. 149 (18), 16885–16904 (2023).
doi: 10.1007/s00432-023-05266-0
pubmed: 37740761
Nedjadi, T. et al. Identification of SPP1 as a prognostic biomarker and immune cells modulator in urothelial bladder cancer: a bioinformatics analysis. Cancers (Basel) 15 (23), 5704 (2023).
Fan, Y. et al. PLCε promotes the Warburg effect and tumorigenesis through AKT/GSK3β/Cdc25a in bladder cancer. Biotechnol. Genet. Eng. Rev. 40 (3), 2155–2169 (2024).
Hao, Y. et al. MicroRNA-30c-5p arrests bladder cancer G2/M phase and suppresses its progression by targeting PRC1-mediated blocking of CDK1/Cyclin B1 axis. Cell. Signal. 110, 110836 (2023).
doi: 10.1016/j.cellsig.2023.110836
pubmed: 37532136
Wu, Y. et al. Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBC. Transl Oncol. 44, 101942 (2024).
doi: 10.1016/j.tranon.2024.101942
pubmed: 38555741
pmcid: 10990904
Min, J. et al. Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription. Clin. (Sao Paulo). 77, 100081 (2022).
doi: 10.1016/j.clinsp.2022.100081
Liu, Y. et al. CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. Cell. Death Dis. 10 (9), 644 (2019).
doi: 10.1038/s41419-019-1894-5
pubmed: 31501420
pmcid: 6733791
Zhu, H. et al. CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis. J. Exp. Clin. Cancer Res. 43 (1), 245 (2024).
doi: 10.1186/s13046-024-03169-7
pubmed: 39210442
pmcid: 11360757
Shen, L. et al. PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder Cancer. Int. J. Biol. Sci. 18 (14), 5459–5474 (2022).
doi: 10.7150/ijbs.74546
pubmed: 36147463
pmcid: 9461664
Cao, Y. et al. LUCAT1 inhibits ferroptosis in bladder cancer by regulating the mRNA stability of STAT3. Gene. 894, 147974 (2024).
doi: 10.1016/j.gene.2023.147974
pubmed: 37944649
Liu, T. et al. ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape. Cell. Death Dis. 14 (12), 800 (2023).
doi: 10.1038/s41419-023-06333-7
pubmed: 38062004
pmcid: 10703795
Luo, Y. et al. PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation. Mol. Carcinog. 62 (7), 907–919 (2023).
doi: 10.1002/mc.23533
pubmed: 37157950
Ma, W. et al. Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1. Protein Cell. 15 (6), 419–440 (2024).
doi: 10.1093/procel/pwae005
pubmed: 38437016
Zhuang, J. et al. Membrane-associated RING-CH 7 inhibits stem-like capacities of bladder cancer cells by interacting with nucleotide-binding oligomerization domain containing 1. Cell. Biosci. 14 (1), 32 (2024).
doi: 10.1186/s13578-024-01210-y
pubmed: 38462600
Maisonneuve, C. et al. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell. Rep. 34 (4), 108677 (2021).
doi: 10.1016/j.celrep.2020.108677
pubmed: 33503439
Zhang, W. & Wang, Y. Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway. Histochem. Cell. Biol. 157 (2), 173–182 (2022).
doi: 10.1007/s00418-021-02055-z
pubmed: 34825931
Shi, X. et al. Eugenol modulates the NOD1-NF-κB signaling pathway via targeting NF-κB protein in triple-negative breast cancer cells. Front. Endocrinol. (Lausanne). 14, 1136067 (2023).
doi: 10.3389/fendo.2023.1136067
pubmed: 36923216
Zhang, Y. et al. Upregulation of NOD1 and NOD2 contribute to cancer progression through the positive regulation of tumorigenicity and metastasis in human squamous cervical cancer. BMC Med. 20 (1), 55 (2022).
doi: 10.1186/s12916-022-02248-w
pubmed: 35130902
pmcid: 8822783